Answers are grounded in this paper and cite their sources.
Introduction Multigene panels for hereditary cancer predisposition have substantially improved diagnostic accuracy and informed risk management strategies. Germline variant interpretation is typically performed according to guidelines from the ACMG-AMP, which classify variants into five categories: benign, likely benign, variant of uncertain significance, likely pathogenic, and pathogenic. The continuous accumulation of scientific evidence may lead to variant reclassification, potentially altering clinical interpretation and patient management. However, structured active reclassification programs remain limited in many settings. Methods This retrospective study evaluated the reclassification rate of germline variants in individuals who underwent multigene panel testing for hereditary cancer predisposition at the Fleury Group between January 2020 and February 2025. Variant monitoring was conducted through an internally developed bioinformatics pipeline that systematically tracks updates in major public variant databases. When new evidence was identified, variants were reassessed by the laboratory’s technical and medical team according to ACMG–AMP guidelines. Variants eligible for reclassification prompted the issuance of an updated clinical report, with notification to both the ordering physician and the patient in accordance with recommended best practices for variant reinterpretation. Results A total of 39 variants across 15 genes were reclassified. Of these, 32 (82%) were upgraded, including 23 (72%) in clinically actionable genes and 9 (28%) in non-actionable genes, while 7 variants (18%) were downgraded, only one of which occurred in an actionable gene. Among 53,574 hereditary cancer panels analyzed during the study period, these reclassification events resulted in 110 updated clinical reports (0.21%), directly impacting clinical management or genetic counseling. Conclusions Active variant reclassification is a feasible strategy with meaningful clinical impact and should be considered an essential component of genetic follow-up programs. These findings also highlight the importance of continuous collaboration among laboratories, clinicians, and patients in the long-term monitoring of genomic data to maximize the clinical utility of genomic medicine.
No takes yet. Share an insight, caveat, or question.
Lima et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: